Clinical Trials

Artiva Biotherapeutics Initiates First U.S. Trial of Allogeneic NK Cell Therapy for Lupus Nephritis

Artiva Biotherapeutics, Inc., a clinical-stage company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell-bas...

 April 18, 2024 | News

Actinogen Medical Launches Phase 2b XanaMIA Trial for Alzheimer's, Marks First Patient Treatment

Actinogen Medical Limited (ASX: ACW) announces that the first patient has been randomized and treated in the XanaMIA phase 2b clin...

 April 16, 2024 | News

Singapore-Based Respiree Expands to U.S., Establishes Presence at Johnson & Johnson Innovation Hub in South San Francisco

Respiree announced that it has incorporated in the US and will be incubating within Johnson & Johnson Innovation – JLABS @ South San Francis...

 April 16, 2024 | News

Teva Validates AJOVY® Efficacy and Safety in China Phase 3 Migraine Trial

AJOVY confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month All critical efficacy endpoints met significanc...

 April 15, 2024 | News

Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer

  These findings build upon the compelling clinical activity demonstrated by BOT/BAL across nine different cancer types in Agenus' broad clinical dev...

 April 13, 2024 | News

Kexing Biopharm Advances Pediatric Care with Phase III Trial of Novel RSV Inhalation Therapy

Kexing Biopharm (688136.SH) announced that the Phase III clinical trial of Human Interferon α1b Inhalation Solution developed by its wholly-owned sub...

 April 11, 2024 | News

BioCity Biopharma's Cancer Therapy BC2027 Gets FDA Nod for Phase 1 Trials

BioCity Biopharma announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for a Pha...

 April 10, 2024 | News

Dizal's Sunvozertinib Secures FDA Breakthrough Therapy Designation for First-Line EGFR Mutated NSCLC Treatment

Dizal announced that the U.S. Food and Drug Administration ("FDA") has granted Breakthrough Therapy Designation (BTD) to its sunvozertinib as the firs...

 April 08, 2024 | News

Ractigen Therapeutics Launches Pioneering Phase I Clinical Trial for Bladder Cancer with First Patient Dosed in Collaboration with GenesisCare

Ractigen Therapeutics, a pioneer in small activating RNA (saRNA) therapeutics, achieved a major milestone with the first patient dosed in its First-in-huma...

 April 04, 2024 | News

YolTech Therapeutics Initiates Clinical Trial for Gene Editing Treatment YOLT-101 Targeting Familial Hypercholesterolemia

YolTech Therapeutics announced that the first patient has been dosed with YOLT-101, the company's in vivo genome editing candidate being develope...

 April 03, 2024 | News

Innovent and HUTCHMED's Endometrial Cancer Therapy Receives Priority Review by China's NMPA

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality me...

 April 03, 2024 | News

Alebund Pharmaceuticals Receives FDA Orphan Drug Designation for AP303 in ADPKD Treatment

 Alebund Pharmaceuticals ("Alebund" or the "Company"), an integrated biopharmaceutical company focusing on developing innovative therapies for th...

 April 01, 2024 | News

GenFleet Therapeutics Collaborates with BeiGene for Advanced Lymphoma Trial

GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced it has entered into ...

 March 29, 2024 | News

Lunit Reveals Positive Study Results for Head and Neck Cancer Immunotherapy

Lunit, a global leader in AI-driven cancer diagnostics and therapy solutions, is thrilled to share the publication of a groundbreaking study in the prestig...

 March 27, 2024 | News


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close